Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy.

ABSTRACT:

Introduction

Cancer Immunotherapy has recently emerged as a promising and effective modality to treat different malignancies. Antigenic profiling of cancer tissues and determination of any pre-existing immune responses to cancer antigens may help predict responses to immune intervention in cancer. NY-ESO-1, a cancer testis antigen is the most immunogenic antigen to date. The promise of NY-ESO-1 as a candidate for specific immune recognition of cancer comes from its restricted expression in normal adult tissue but frequent occurrence in multiple tumors including melanoma and carcinomas of lung, esophageal, liver, gastric, prostrate, ovarian, and bladder.

Main body

This review summarizes current knowledge of NY-ESO-1 as efficient biomarker and target of immunotherapy. It also

SUBMITTER: Raza A 

PROVIDER: S-EPMC7102435 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature